secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2026-08-13T20:02:20+00:00
Accession:  0001493152-26-037736
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Q2 net loss $4.8M; raises $8.6M; AKTX-101 on track for mid-2027 Phase 1
-----------------------------------------------------------------------------

- Q2 2026 net loss $4.8M vs $1.9M YoY; R&D $2.1M up from $0.7M on IND-enabling work.
- Cash $7.7M at June 30, 2026 vs $5.2M at Dec 31, 2025; raised $8.6M gross in quarter.
- AKTX-101 progressing toward Phase 1 initiation planned for mid-2027; ASCO data on PH1 + KRAS inhibitor.
- Research collaboration with Whitehawk Therapeutics on dual-payload ADCs combining PH1 with topoisomerase I payload.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000149315226037736/0001493152-26-037736-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000149315226037736/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-037736

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer